Clinical Trials Logo
  1. Home
  2. Urinary Bladder, Neurogenic
  3. NCT02044510

Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients

Urinary Bladder, Neurogenic Clinical Trial

Official title:
A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients

Clinical Trial Summary

The proposed study is a randomized, double blind placebo controlled multicenter study to determine the effectiveness of mirabegron in the treatment of neurogenic bladder dysfunction. Patients will be randomized into one of two trial arms: mirabegron 25mg for two weeks, with escalation to 50mg for the remaining 8 weeks, or matched placebo capsule for two weeks, with placebo escalation for the remaining 8 weeks. Each of these trial arms will be stratified based on whether the patient is already taking an anticholinergic medication or not. The study will treat a total of 144 patients (72 with placebo, 72 with mirabegron). The study hypothesis is that mirabegron will result in a statistically superior (increased) urodynamic bladder capacity.

The study duration is 12 weeks, with a 1-4 week run in period where no active or placebo treatment will be administered. The primary outcome measure will be based on an increase in urodynamic bladder capacity. Secondary outcome measures will be additional urodynamic parameters, urinary symptom scales, urinary quality of life indices, and voiding diary results.

Patients who are over 18 years of age with a diagnosis of multiple sclerosis (MS) or spinal cord injury (SCI) will be eligible to participate. All eligible patients will have urodynamic studies performed within 4 weeks of trial enrollment, and at the end of study (week 9-10). Adverse events and study outcomes will be assessed at predefined study time points.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02044510
Study type Interventional
Source Lawson Health Research Institute
Contact
Status Terminated
Phase Phase 2/Phase 3
Start date July 2014
Completion date February 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05141487 - Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder
Completed NCT01920243 - Evaluation of a Bowel and Bladder Health Management Program for Individuals With Spinal Cord Injury (SCI) N/A
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Enrolling by invitation NCT03336424 - Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations. N/A
Not yet recruiting NCT05075642 - Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis
Completed NCT02600715 - Reduction of Bladder Injection Pain With Belladonna Opiate Suppository Phase 4
Recruiting NCT04128709 - Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use N/A
Enrolling by invitation NCT05740527 - Ambulatory Closed-loop Stimulation for Bladder Control N/A
Completed NCT02501928 - Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity. Phase 3
Recruiting NCT06336304 - NXT Post-Market Clinical Follow-up
Completed NCT06445426 - Cystometry Using a Novel Microsensor System in Patients With Neurogenic Bladder Dysfunction
Recruiting NCT04819360 - Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis Phase 4
Completed NCT01557244 - A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition Phase 3
Recruiting NCT05380661 - Heart Rate Variability and Anxiety During Urinary Bladder Catheterization N/A
Recruiting NCT04193709 - Recovery of Bladder and Sexual Function After Human Spinal Cord Injury N/A
Completed NCT02582151 - Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder N/A
Active, not recruiting NCT05232253 - Cystoealstometer (Bladder Monitor Device)-Home Use N/A
Completed NCT03405285 - Connected Catheter Clinical Feasibility Study( CFS) N/A
Completed NCT02673047 - Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder N/A
Completed NCT01773213 - Detrusor Contraction During the Ice-water-test N/A